NCT06509958

Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKA

A Phase Ⅱ Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Single Injection Adductor Canal Block With HR18034 for Postoperative Pain Management in Total Knee Arthroplasty

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase Ⅱ, randomized, double-blind, comparator-controlled study to evaluate the efficacy, safety and pharmacokinetics of single injection adductor canal block with HR18034 for postoperative pain management in total knee arthroplasty compared with ropivacaine.

Conditions

• Postoperative Pain Management in Total Knee Arthroplasty

Interventions

Type	Name	Description
DRUG	HR18034	HR18034
DRUG	Ropivacaine Hydrochloride Injection	Ropivacaine Hydrochloride Injection

Timeline

• Start date: 2024-08-20
• Primary completion: 2024-10-10
• Completion: 2024-10-10
• First posted: 2024-07-19
• Last updated: 2024-10-30

Locations

1 site across 1 country: China